By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Sodium phenylacetate and sodium benzoate (monograph)
Drugs

Sodium phenylacetate and sodium benzoate (monograph)

https://themeditary.com/drug/sodium-phenylacetate-and-sodium-benzoate-monograph-6524.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Aug 14, 2023  Additional Content by TheMediTary.Com

Generic name: medically reviewed

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Ammonul

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Sodium phenylacetate and sodium benzoate (monograph)?

Introduction

Fixed combination of 2 ammonia detoxicants.

Uses for Sodium Phenylacetate and Sodium Benzoate

Acute Hyperammonemia

Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (e.g., deficiency in carbamyl phosphate synthetase [CPS], ornithine transcarbamylase [OTC], argininosuccinate synthetase [ASS], or argininosuccinate lyase [ASL]); designated an orphan drug by FDA for this use.

Treat any episode of acute symptomatic hyperammonemia as a life-threatening emergency; prompt use of all necessary therapies (e.g., dialysis [preferably hemodialysis], caloric supplementation, protein restriction) to reduce ammonia concentrations is essential.

Hemodialysis is the preferred therapy for acute neonatal hyperammonemic coma, moderate to severe episodes of hyperammonemic encephalopathy, and episodes of hyperammonemia that fail to respond to an initial course of sodium phenylacetate and sodium benzoate therapy. In such patients, administration of sodium phenylacetate and sodium benzoate helps prevent reaccumulation of ammonia by increasing waste nitrogen excretion.

Concomitant therapy with IV arginine hydrochloride is required in patients with CPS, OTC, ASS, or ASL deficiency; however, IV arginine hydrochloride is contraindicated in patients with arginase deficiency. Pending specific diagnosis, also give IV arginine hydrochloride to hyperammonemic infants with suspected urea cycle disorders.

If a urea cycle disorder is suspected based on family history, document hyperammonemia before administering sodium phenylacetate and sodium benzoate.

Sodium Phenylacetate and Sodium Benzoate Dosage and Administration

General

  • Initiate therapy immediately following the diagnosis of hyperammonemia.

  • Prior to infusion, discontinue analogous oral agents (e.g., sodium phenylbutyrate).

  • May administer an antiemetic during the infusion for management of possible nausea and vomiting.

  • Start or resume oral therapy (e.g., sodium phenylbutyrate), dietary management, and protein restriction when ammonia concentrations reduced to the normal range.

  • Dialysis is recommended for those patients who do not have a significant reduction in plasma ammonia levels within 4–8 hours after receiving sodium phenylacetate and sodium benzoate.

  • Concomitant therapy with arginine hydrochloride may be required. Consult the prescribing information for arginine hydrochloride for complete dosing and other information.

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion through a central venous line only; administration through a peripheral line may cause burns.

Vials are for single use only.

Dilution

Mustbe diluted in 10% dextrose injection prior to administration.

Always use the Millex Durapore GV 33-mm sterile syringe filter (0.22 µm) provided by the manufacturer when diluting sodium phenylacetate and sodium benzoate injection regardless of whether particulate matter is visible in the vial. Particulate matter has been reported but may notbe readily observed on visual inspection; removal of these particulates by this filter has been confirmed. (See Detection of Particulate Matter in Commercial Preparations under Cautions.)

Prepare IV infusion in glass or PVC container.

Determine the volume of diluent based on the patient’s weight (neonates, infants, and children weighing ≤20 kg) or BSA (children weighing >20 kg, adolescents, and adults). Dilute each loading or maintenance dose of injection concentrate in ≥25 mL/kg of body weight of 10% dextrose injection.

Rate of Administration

Administer loading dose over 90–120 minutes.

Administer maintenance dose over 24 hours.

Dosage

Available as sodium phenylacetate and sodium benzoate; dosage expressed in terms of the salts.

Base dosages in neonates, infants, and children weighing ≤20 kg on body weight; base dosages in pediatric patients weighing >20 kg and in adults on body surface area.

Pediatric Patients

Acute Hyperammonemia
IV

Pediatric patients weighing ≤20 kg: Loading dose of 250 mg/kg sodium phenylacetate in fixed combination with 250 mg/kg sodium benzoate infused over 90–120 minutes. Maintenance dose of 250 mg/kg of sodium phenylacetate and 250 mg/kg sodium benzoate infused over 24 hours.

Pediatric patients weighing >20 kg: Loading dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Maintenance dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 of sodium benzoate infused over 24 hours.

Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

Repeat Loading Doses
IV

Manufacturer states do not repeat loading doses; however, some experts state that a repeat loading dose within 24 hours should be considered only in neonates with severe disorders and/or those receiving dialysis; space loading doses ≥6 hours apart. (See Laboratory Monitoring and also see Repeat Loading Doses under Cautions.)

Adults

Acute Hyperammonemia
IV

Loading dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Manufacturer states do not repeat loading doses.

Maintenance dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 24 hours.

Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

Special Populations

No special population dosage recommendations at this time. (See Hepatic Impairment and see Renal Impairment under Cautions and also see Special Populations under Pharmacokinetics.)

Detailed Sodium benzoate / sodium phenylacetate dosage information

Warnings

Contraindications

  • Known hypersensitivity to sodium phenylacetate or sodium benzoate or any ingredient in the formulation.

Warnings/Precautions

Warnings

Emergency Treatment of Hyperammonemia

Risk of rapid brain damage or death if acute symptomatic hyperammonemia is left uncontrolled; treat as a life-threatening emergency. Prompt use of all therapies to reduce serum ammonia concentrations (e.g., dialysis [preferably hemodialysis]) is essential. (See Acute Hyperammonemia under Uses.)

Manage hyperammonemia due to inborn errors of metabolism in coordination with medical personnel familiar with such conditions; usually requires health-care facilities able to provide multidisciplinary treatment (e.g., hemodialysis, nutritional management, medical support).

Laboratory Monitoring

Closely monitor plasma ammonia concentrations, neurologic status, laboratory tests, and clinical response during treatment.

Monitor serum electrolyte concentrations; maintain within the normal range.

Urinary loss of potassium is enhanced by excretion of nonabsorbable anions phenylacetylglutamine and hippurate; carefully monitor plasma potassium concentrations and provide replacement therapy, when necessary.

Perform blood chemistry profiles and frequent blood pH and blood gases (e.g., pCO2) evaluations to check for salicylate-like toxicity. (See Salicylate-like Toxicity under Cautions.)

The Urea Cycle Disorders Conference Group and some experts recommend monitoring plasma concentrations of ammonia scavenging drugs (e.g., sodium phenylacetate and sodium benzoate) to avoid toxicity. Weigh the risk of overdosage against potential benefits of repeating a loading dose in the absence of facilities for drug concentration monitoring. (See Repeat Loading Doses under Dosage and Administration and also see Repeat Loading Doses under Cautions.)

Possible Prescribing Errors

Experts recommend double-checking the accuracy of prescription orders to avoid possible overdosage.

Detection of Particulate Matter in Commercial Preparations

Particulate matter has been detected in sodium phenylacetate and sodium benzoate injections. Particulates may notbe readily observed on visual inspection. Because these particulates could potentially affect injection safety, always use the Millex Durapore GV 33-mm sterile syringe filter (0.22 µm) provided by the manufacturer when diluting the injection (see Dilution under Dosage and Administration). Removal of these particulates by this filter has been confirmed.

Report any quality problems or suspected adverse effects to the manufacturer (800-900-6389) or the FDA MedWatch program.

For addditional information, see [Web] or [Web].

Extravasation

Do not administer injection concentrate undiluted; only administer via a central line. Peripheral venous administration may cause burns.

Extravasation into perivenous tissue may lead to skin necrosis. Carefully monitor the infusion site during infusion. If extravasation is suspected, discontinue the infusion and resume at a different site, if necessary. Treatment for extravasation may include aspiration of residual drug from the catheter, limb elevation, and intermittent cooling with cold packs.

Sodium Content

Each g of sodium phenylacetate provides 6.3 mEq (145 mg) of sodium, and each g of sodium benzoate provides 7 mEq (160 mg) of sodium; each mL of injection concentrate labeled as containing 100 mg each of sodium phenylacetate and sodium benzoate provides 1.33 mEq (30.5 mg) of sodium.

Consider sodium content and use with caution, if at all, in patients with CHF, severe renal impairment, or sodium retention with edema. If adverse effects associated with increased sodium concentrations occur, discontinue the drug, promptly evaluate the patient, and take appropriate measures.

Salicylate-like Toxicity

Structurally similar to salicylate; possibility of adverse effects (e.g., hyperventilation, metabolic acidosis) typically associated with acute salicylate toxicity. (See Laboratory Monitoring under Cautions.)

Major Toxicities

Neurotoxicity

Adverse neurotoxic effects (e.g., somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, exacerbation of existing neuropathy) reported in cancer patients receiving IV phenylacetate. Acute onset (mainly mild) occurred upon initiation of therapy; reversible upon discontinuance of the drug.

General Precautions

Repeat Loading Doses

The manufacturer states that, because plasma concentrations of phenylacetate are prolonged, do not repeat loading doses. However, some experts state that a repeat loading dose within 24 hours should be considered only in neonates with severe disorders and/or those receiving dialysis; space loading doses at least 6 hours apart. (See Repeat Loading Doses under Dosage and Administration and see Laboratory Monitoring under Cautions.)

Hyperbilirubinemia

Risk of indirect hyperbilirubinemia. Use with caution in neonates with hyperbilirubinemia. In infants at risk, reduce serum bilirubin concentrations to normal range before initiating therapy with sodium phenylacetate and sodium benzoate.

Dialysis

Manufacturer states drug is complementary with dialysis (e.g., standard hemodialysis, peritoneal dialysis, arteriovenous hemofiltration).

Specific Populations

Pregnancy

Category C.

Lactation

Not known whether sodium phenylacetate or sodium benzoate or their conjugated metabolites are distributed into milk. Use with caution in nursing women.

Pediatric Use

Efficacy is established for treatment of hyperammonemia in pediatric patients 0–16 years of age, including neonates (0–30 days of age) and infants (31 days–2 years of age).

Use with caution in neonates with hyperbilirubinemia. (See Hyperbilirubinemia under Cautions.)

Hepatic Impairment

Use with caution in patients with hepatic impairment. (See Metabolism under Pharmacokinetics.)

Renal Impairment

Use with caution and carefully monitor patients with renal impairment. (See Elimination under Pharmacokinetics.)

Common Adverse Effects

Vomiting, hyperglycemia, hypokalemia, seizures, mental impairment.

How should I use Sodium phenylacetate and sodium benzoate (monograph)

General

  • Initiate therapy immediately following the diagnosis of hyperammonemia.

  • Prior to infusion, discontinue analogous oral agents (e.g., sodium phenylbutyrate).

  • May administer an antiemetic during the infusion for management of possible nausea and vomiting.

  • Start or resume oral therapy (e.g., sodium phenylbutyrate), dietary management, and protein restriction when ammonia concentrations reduced to the normal range.

  • Dialysis is recommended for those patients who do not have a significant reduction in plasma ammonia levels within 4–8 hours after receiving sodium phenylacetate and sodium benzoate.

  • Concomitant therapy with arginine hydrochloride may be required. Consult the prescribing information for arginine hydrochloride for complete dosing and other information.

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion through a central venous line only; administration through a peripheral line may cause burns.

Vials are for single use only.

Dilution

Mustbe diluted in 10% dextrose injection prior to administration.

Always use the Millex Durapore GV 33-mm sterile syringe filter (0.22 µm) provided by the manufacturer when diluting sodium phenylacetate and sodium benzoate injection regardless of whether particulate matter is visible in the vial. Particulate matter has been reported but may notbe readily observed on visual inspection; removal of these particulates by this filter has been confirmed. (See Detection of Particulate Matter in Commercial Preparations under Cautions.)

Prepare IV infusion in glass or PVC container.

Determine the volume of diluent based on the patient’s weight (neonates, infants, and children weighing ≤20 kg) or BSA (children weighing >20 kg, adolescents, and adults). Dilute each loading or maintenance dose of injection concentrate in ≥25 mL/kg of body weight of 10% dextrose injection.

Rate of Administration

Administer loading dose over 90–120 minutes.

Administer maintenance dose over 24 hours.

Dosage

Available as sodium phenylacetate and sodium benzoate; dosage expressed in terms of the salts.

Base dosages in neonates, infants, and children weighing ≤20 kg on body weight; base dosages in pediatric patients weighing >20 kg and in adults on body surface area.

Pediatric Patients

Acute Hyperammonemia
IV

Pediatric patients weighing ≤20 kg: Loading dose of 250 mg/kg sodium phenylacetate in fixed combination with 250 mg/kg sodium benzoate infused over 90–120 minutes. Maintenance dose of 250 mg/kg of sodium phenylacetate and 250 mg/kg sodium benzoate infused over 24 hours.

Pediatric patients weighing >20 kg: Loading dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Maintenance dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 of sodium benzoate infused over 24 hours.

Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

Repeat Loading Doses
IV

Manufacturer states do not repeat loading doses; however, some experts state that a repeat loading dose within 24 hours should be considered only in neonates with severe disorders and/or those receiving dialysis; space loading doses ≥6 hours apart. (See Laboratory Monitoring and also see Repeat Loading Doses under Cautions.)

Adults

Acute Hyperammonemia
IV

Loading dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Manufacturer states do not repeat loading doses.

Maintenance dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 24 hours.

Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

Special Populations

No special population dosage recommendations at this time. (See Hepatic Impairment and see Renal Impairment under Cautions and also see Special Populations under Pharmacokinetics.)

Detailed Sodium benzoate / sodium phenylacetate dosage information
Sodium phenylacetate and sodium benzoate (monograph) Dosage information (more detail)

What other drugs will affect Sodium phenylacetate and sodium benzoate (monograph)?

No formal drug interaction studies to date.

Specific Drugs

Drug

Interaction

Anti-infective agents (e.g., penicillin)

Some anti-infective agents may compete with phenylacetylglutamine and hippurate for active renal tubular secretion, affecting drug disposition

Corticosteroids

Corticosteroids may increase plasma ammonia concentrations by causing protein catabolism

Probenecid

Probenecid inhibits renal transport of organic compounds (including aminohippuric acid)

Probenecid may affect renal excretion of phenylacetylglutamine and hippurate

Valproic acid

Valproic acid may induce hyperammonemia via inhibition of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase

Concomitant use may exacerbate urea cycle disorders and antagonize plasma ammonia-lowering effects of the ammonia detoxicant

More about Sodium phenylacetate and sodium benzoate (monograph) (Medically reviewed)

Dosage information
Sodium phenylacetate and sodium benzoate (monograph) Side Effects
During pregnancy
Sodium Phenylacetate and Sodium Benzoate Concentrate Injection Prescribing Information
Drug images
Side effects
Drug class: Drugs

Patient resources

Sodium Phenylacetate and Sodium Benzoate

Related treatment guides

Hyperammonemia
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by